CORT · Corcept Therapeutics Incorporated · Stock research

Current Thesis

The August question was whether the post-print gap would hold or fill. It held and extended: the 2026-08-21 close of $122.25 is the 52-week high, 0.0% off it, roughly 10% above the 2026-08-07 close of $110.77 — and no company-specific headline has printed since 2026-07-30. That is the important change. The leg an investor is buying is no longer "will the oncology launch be real"; the 2026-07-29 report answered that with Lifyorli (relacorilant + nab-paclitaxel) revenue of $47.6M in its first quarter of availability, total revenue $256.1M versus $219.99M consensus, and an FY2026 guide taken to $1.1–1.2B from $950M–$1.05B against a $1.008B street number. What is being bought now is the ramp continuing through a quiet stretch and the second approval landing on 2026-12-17. Between here and that date the calendar is thin: ESMO Congress 2026 runs 23–27 October in Madrid with no confirmed Corcept presentation, and Q3 results are unscheduled but historically early November. Price is discounting continuation with no dated event to check it against for roughly three months.

Bullish and bearish views on Corcept Therapeutics Incorporated

The model's bull view on Corcept Therapeutics Incorporated (CORT), in brief: The launch quarter was a number, not a forecast. The bear view: Form 4s were filed 2026-08-18 and 2026-08-20. Both cases follow in full.

Bull Case

• The launch quarter was a number, not a forecast. Lifyorli revenue $47.6M in Q2 2026, its first quarter of availability, with more than 1,300 patients started since the 2026-03-25 FDA approval (Q2 press release, 2026-07-29).
• Guidance was raised by more than the beat. FY2026 revenue guide to $1.1–1.2B from $950M–$1.05B on 2026-07-29 — the second raise of the year after the 2026-04-30 lift — against $1.008B consensus.
• The endocrine base is still growing. Korlym plus authorized-generic revenue $208.6M in Q2 2026 versus $194.4M in Q2 2025, so oncology revenue is additive to the base rather than cannibalising it.
• Total revenue +32% YoY to $256.1M with diluted EPS $0.36 against a $(0.00) consensus and net income $43.0M versus $35.1M a year earlier.
• The second approval carries a date. The Cushing's/hypercortisolism NDA, resubmitted 2026-06-17, has a PDUFA target action date of 2026-12-17; the resubmission adds analyses of the existing dataset rather than new trials.
• Self-funded into that decision. Cash and investments $544.6M at 2026-06-30, up from $515.4M at 2026-03-31, with no financing disclosed into the review.
• Sell-side targets sit above spot. Piper Sandler Overweight PT $165 (from $88) and HC Wainwright Buy PT $165 on 2026-07-30; Canaccord Genuity Buy PT $161 the same day.

Bear Case

• Form 4s were filed 2026-08-18 and 2026-08-20.
• The corporate bid that absorbed prior drawdowns is effectively spent.
• A three-month vacuum. No company-confirmed binary sits between now and 2026-12-17. BELLA Part A topline, the ROSELLA EU MAA decision and the MONARCH Phase 2b MASH readout were all guided only to "end of 2026" on the Q2 call.
• The dispersion has not converged. Wolfe Research downgraded to Underperform with a $50 target on 2026-07-27, two days before the beat, and has not been reported as revising it; the $50-to-$165 spread is a 3.3x range on one asset. At $122.25 the stock trades above the mid-point of that range and inside 26% of the top of it.
• The PDUFA is a re-run of a failed review. The original hypercortisolism NDA drew a Complete Response Letter. A second non-approval removes an option the current multiple embeds and arrives with no offsetting catalyst behind it.
• Move size. The shares are up 103% over three months into 2026-08-21 and sit at the 52-week high, so any disappointment is measured against a price that already assumes the ramp.

Setup & Price Structure

Last completed daily close $122.25 (2026-08-21), equal to the 52-week high, with RSI(14) at 66.3 — extended but not at a momentum extreme. The structure below is unusually hollow: the 2026-07-30 gap, which followed a +21.95% after-hours move on the print, left almost no traded shelf between the pre-print area near $92 and post-print levels. The reference points that exist are the 2026-08-07 close of $110.77, which marks the base the stock built before this leg, and the $92 pre-print shelf beneath the gap. A weekly close under $100 would put price back inside the gap with nothing between it and $92.

The narrative is maturing. The dating for that label is the news flow, not the price. The last company-specific headlines are all clustered 2026-07-29 to 2026-07-30 — the print, the guidance raise, three price-target increases. Since then the tape has added roughly 10% on no new disclosure while the marginal seller identified in filings is an insider (2026-08-17 Form 144). That is a well-known story still working with a thinning stream of fresh reasons, which is what separates it from accelerating; there is no evidence of structure failure that would justify saturated or dead.

Crowding and positioning observables, stated as observables: institutional and hedge-fund ownership reported at 93.61% (MarketBeat, August 2026); price 0.0% below the 52-week high; two insider disposals and one proposed-sale notice inside 15 sessions; a buyback authorization drawn down to $188.58M of $200M with zero repurchases in the June quarter; no company-confirmed event inside 30 days.

Catalyst Calendar (next 30 days)

• No company-confirmed event falls between 2026-08-22 and 2026-09-21. This is the defining feature of the window, not an omission.
• ~2026-09-15 (est.) — September healthcare investor-conference season (Morgan Stanley, Wells Fargo, HC Wainwright all run early-to-mid September). Corcept participation is unconfirmed; a presentation would be the only scheduled venue for a Lifyorli ramp update before Q3.
• Through ~2026-11-15 — further Form 4s would date the execution.
• 2026-10-23 to 2026-10-27 — ESMO Congress 2026, IFEMA Madrid (confirmed congress dates). Corcept presented ROSELLA late-breaking data at ESMO 2025 on 2025-10-19; whether relacorilant features in 2026 is unconfirmed, and abstract titles typically post roughly two weeks ahead.
• ~2026-11-04 (est.) — Q3 2026 results. First read on sequential Lifyorli growth off the $47.6M Q2 line and on whether the $1.1–1.2B FY guide moves again.
• 2026-12-17 — PDUFA target action date, relacorilant for hypercortisolism.

What Would Change Our Mind

The structure that would have to fail first is the 2026-07-30 print gap — the only thing separating current price from the $92 pre-print shelf. A weekly close below $100 puts price back inside that gap and returns the stock to pre-guidance-raise territory, which would say the market has stopped paying for the FY2026 raise.

On fundamentals, the checkable disconfirmations are dated: Q3 2026 Lifyorli revenue at or below the $47.6M reported for Q2, a trim to the $1.1–1.2B FY guide, or Korlym plus authorized-generic revenue printing below $208.6M sequentially. On the calendar, an FDA action on or before 2026-12-17 that is not an approval — or a disclosed three-month extension to the review clock — removes the option the post-print multiple embeds.

The narrative would also break without a price event: if ESMO 2026 (23–27 October) passes with no relacorilant data and Q3 shows a flattening ramp, the name enters 2027 as a single-product endocrinology company with a pending Cushing's decision, which is closer to how it traded near $60 in May 2026 than to $122.

Correlation Notes

Moves here are idiosyncratic. The two largest of 2026 attach to company events — the 2026-03-25 Lifyorli approval and the 2026-07-29 print, which produced a +21.95% after-hours reaction — not to sector beta. With reported institutional and hedge-fund ownership at 93.61% (MarketBeat, August 2026), passive and ETF flow is a small share of the float, so rotation out of a concentrated holder base amplifies both directions.

Two external read-throughs are worth tracking. First, competitive: platinum-resistant ovarian cancer already has an antibody-drug-conjugate standard in the folate-receptor-alpha population, so competitor label expansions or data in PROC bear directly on the Lifyorli ramp that Q3 has to demonstrate. Second, regulatory throughput: with the whole second-approval leg resting on a single 2026-12-17 action date, FDA review-timeline disruption is a shared risk with every other name carrying a Q4 PDUFA, and it is not diversifiable inside this position of the calendar. Korlym's active ingredient is mifepristone, which gives the base franchise a political headline exposure unconnected to either the oncology or Cushing's thesis.